Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 15/20 | 0.76 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292855 | 0.91 | PLA2G2A (0.73) | PLA2G2APLA2G1BPTGS2 | |
| SCHEMBL8296740 | 0.88 | PLA2G2A (0.81) | PLA2G2A | |
| SCHEMBL8291679 | 0.88 | PLA2G2A (0.76) | PLA2G2APLA2G1B | |
| SCHEMBL8301080 | 0.85 | PLA2G2A (0.66) | PLA2G2APLA2G1BPTGS2 | |
| SCHEMBL8301180 | 0.84 | PLA2G2A (0.74) | PLA2G2APLA2G1BPTGS2 | |
| SCHEMBL7962081 | 0.84 | PLA2G2A (0.80) | PLA2G2APLA2G1BPTGS2 | |
| SCHEMBL7962138 | 0.83 | PLA2G2A (0.79) | PLA2G2APLA2G1BPTGS2 | |
| SCHEMBL8292902 | 0.83 | PLA2G2A (0.76) | PLA2G2APLA2G1BPTGS2 | |
| SCHEMBL8978243 | 0.83 | PLA2G2A (0.66) | PLA2G2APLA2G1BPTGS2 | |
| SCHEMBL8292514 | 0.83 | PLA2G2A (0.75) | PLA2G2APLA2G1BPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0620214-B1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | LILLY CO ELI (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5578634-A | SEPTIC SHOCK TREATMENT | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0620214-A1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |